MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome

Gut

Volumn 59, Issue 6, 2010, Pages 775-784

  Zhou, QiQi ^a,b   Souba, Wiley W ^a   Croce, Carlo M ^a   Verne, G Nicholas ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE AMMONIA LIGASE; LACTULOSE; MANNITOL; MICRORNA; MICRORNA 29A; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CELL MEMBRANE PERMEABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; MEMBRANE MICROPARTICLE; PRIORITY JOURNAL; REGULATORY MECHANISM;

ADULT; BASE SEQUENCE; CELLS, CULTURED; COLON; CYTOPLASMIC VESICLES; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUTAMATE-AMMONIA LIGASE; HUMANS; INTESTINAL ABSORPTION; IRRITABLE BOWEL SYNDROME; MALE; MICRORNAS; PERMEABILITY; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 77953721053     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.181834     Document Type: Article

References (53)

1. Verne GN, Cerda JJ. Irritable bowel syndrome. Streamlining the diagnosis. Postgrad Med 1997;102:197-208.
2. Verne GN, Himes NC, Robinson ME, et al. Central representation of visceral and cutaneous hypersensitivity in the irritable bowel syndrome. Pain 2003;103:99-110.
3. Verne GN, Robinson ME, Price DD. Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome. Pain 2001;93:7-14.
4. Dunlop SP, Hebden J, Campbell E, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006;101:1288-94.
5. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47:804-11.
6. Spiller RC. Role of infection in irritable bowel syndrome. J Gastroenterol 2007;42 (Suppl 17):41-7.
7. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hyper-sensitivity in the irritable bowel syndrome. Pain 2009;146:41-6.
8. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995;108:1566-81.
9. Keshavarzian A, Holmes EW, Patel M, et al. Leaky gut in alcoholic cirrhosis: a possible mechanism for alcohol-induced liver damage. Am J Gastroenterol 1999;94:200-7.
10. Keshavarzian A, Fields JZ, Vaeth J, et al. The differing effects of acute and chronic alcohol on gastric and intestinal permeability. Am J Gastroenterol 1994;89:2205-11. (Pubitemid 24363671)
11. Al Chaer ED, Kawasaki M, Pasricha PJ. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology 2000;119:1276-85.
12. Mayer EA, Collins SM. Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology 2002;122:2032-48.
13. Zhou Q, Caudle RM, Price DD, et al. Visceral and somatic hypersensitivity in a subset of rats following TNBS-Induced colitis. Pain 2008;134:9-15. (Pubitemid 350251000) (Pubitemid 350251000)
14. Häberle J, Görg B, Rutsch F, et al. Congenital glutamine deficiency with glutamine synthetase mutations. N Engl J Med 2005;353:1926-33.
15. Souba WW, Klimberg VA, Plumley DA, et al. The role of glutamine in maintaning a healthy gut and supporting the metabolic response to injury and infection. J Surg Res 1990;48:383-91.
16. Klimberg VA, Souba WW. The importance of intestinal glutamine metabolism in maintaining a healthy gastrointestinal tract and supporting the body's response to injury and illness. Surg Annu 1990;22:61-76.
17. Labow BI, Souba WW. Glutamine. World J Surg 2000;24:1503-13.
18. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNA and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007;9:654-9
19. Fevrier B, Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol 2004;16:415-21.
20. Greenwalt TJ. The how and why of exocytic vesicles. Transfusion 2006;46:143-52.
21. Hugel B, Martinez MC, Kunzelmann C, et al. Membrane microparticles: two sides of the coin. Physiology (Bethesda) 2005;20:22-7. (Pubitemid 40363367)
22. Pap E, Pallinger E, Paszoi M, et al. Highlights of a new type of intercellular communication microvesicle-based information transfer review. Inflamm Res 2009;58:1-8.
23. Geijnen HF, Schiel AE, Fijnheer R, et al. Activated platelets release two types of membrane vesicles: micrivesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 1999;94:3791-9.
24. VanWijk MJ, VanBavel E, Sturk A, et al. Microparticles in cardiovascular diseases. Cardiovasc Res 2003;59:277-87.
25. Horstmann LL, Jy W, Jimenez JJ, et al. New horizons in the analysis of circulating cell-derived microparticles. Keio J Med 2004;53:210-30.
26. Ratajczak J, Wysoczynski M, Hayek F, et al. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006;20:1487-95.
27. Sloand EM, Mainwaring L, Keyvanfar L, et al. Transfer of glycosylphosphatidylinositol-anchored proteins to deficient cells after erythrocyte transfusion in paroxysmal nocturnal hemoglobinuria. Blood 2004;104:3782-8.
28. Kim J, Krichevsky A, Grad Y, et al. Identification of many microRNAs that copurify with polyribomes in mammalian neurons. Proc Natl Acad Sci U S A 2004;101:360-5.
29. Farh KK, Grimson A, Jan C, et al. The widespread impact of mammalian microRNA on mRNA repression and evolution. Science 2005;310:1817-21.
30. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltranferases 3A and 3B. Proc Natl Acad Sci USA 2007;104:15805-10.
31. Vanner S. The lactulose breath test for diagnosing SIBO in IBS patients: another nail in the coffin. Am J Gastroenterol 2008;103:964-5.
32. Bratten JR, Spainer J, Jones MP. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol 2008;103:958-63.
33. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91.
34. Camilleri M, Nadeau A, Lamsam J, et al. Understanding measurements of intestinal permeability in healthy humans with urine lactulose and mannitol exretion. Neurogastroenterol Motil 2010 22:e15-26.
35. Leonards KS, Ohki S. Isolation and characterization of large (0.5-1.0 μm) cytoskeleton-free vesicles from human and rabbit erythrocytes. Biochim Biophys Acta 1983;728:383-93. (Pubitemid 13117989)
36. o(D) antigen in cytoskeleton-free vesicles. Transfusion 1987;27:32-5.
37. Liu C, Calin GA, Volinia S, et al. MicroRNA expression profiling using microarrays. Nat Protoc 2008;3:563-78.
38. Siddiqui KM, Chopra DP. Primary and long term epithelial cell cultures from human fetal normal colonic mucosa. In Vitro 1984;20:859-68.
39. Smith HS. In vitro properties of epithelial cell lines established from human carcinomas and nonmalignant tissue. J Natl Cancer Inst 1979;62:225-30.
40. Macdonald TT, Montelenone G. Immunity, inflammation, and allergy in the gut. Science 2005;307:1920-5.
41. Porras M, Martín MT, Yang PC, et al. Correlation between cyclical epithelial barrier dysfunction and bacterial translocation in the relapses of intestinal inflammation. Inflamm Bowel Dis 2006;12:843-52.
42. Camilleri M, Gorman H. Intestinal permeability and irritable bowel syndrome. Neurogastroenterol Motil 2007;19:545-52.
43. Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 2003;124:1662-71.
44. Dupont AW. Post-infectious irritable bowel syndrome. Curr Gastroenterol Rep 2007;9:378-84.
45. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004;53:1096-2011.
46. Yoshida S, Matsui M, Shirouzu Y, et al. Effects of glutamine supplements and radiochemotherapy on the systemic immune and gut barrier function in patients with advanced esophageal cancer. Ann Surg 1998;227:485-91.
47. Sido B, Seel C, Hochlehnert A, et al. Low intestinal glutamine level and low glutaminase activity in Crohn's disease: a rational for glutamine supplementation? Dig Dis Sci 2006;51:2170-9.
48. DeMarco V, Dyess K, Strauss D, et al. Inhibition of glutamine synthetase decreases proliferation of cultured rat intestinal epithelial cells. J Nutr 1999;129:57-62. (Pubitemid 29044758)
49. Halicka HD, Bedner E, Darzynkiewicz Z. Segregation of RNA and separate packaging of DNA and RNA in apoptotic bodies during apoptosis. Exp Cell Res 2000;260:248-56.
50. Levine SJ. Mechanisms of soluble cytokine receptor generation. J Immunol 2004;173:5343-8.
51. Taback B, Hoon DS. Circulating nucleic acids and proteomics of plasma/serum: clinical utility. Ann N Y Acad Sci 2004;1022:1-8.
52. Wu F, Zikusoka M, Trindade A, et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2α. Gastroenterology 2008;135:1624-35.
53. Kapeller J, Houghton LA, Monnikes H, et al. First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Mol Genet 2008;17:2967-77.